Form 8-K - Current report:
SEC Accession No. 0001698530-25-000004
Filing Date
2025-01-22
Accepted
2025-01-22 17:02:46
Documents
15
Period of Report
2025-01-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xcur-20250119.htm   iXBRL 8-K 27696
2 EX-99.1 ex991pressrelease12225.htm EX-99.1 12353
6 exicureimage1a10.gif GRAPHIC 2794
  Complete submission text file 0001698530-25-000004.txt   172108

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xcur-20250119.xsd EX-101.SCH 1788
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xcur-20250119_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xcur-20250119_pre.xml EX-101.PRE 12512
17 EXTRACTED XBRL INSTANCE DOCUMENT xcur-20250119_htm.xml XML 2706
Mailing Address 2430 N. HALSTED ST. CHICAGO IL 60614
Business Address 2430 N. HALSTED ST. CHICAGO IL 60614 847-673-1700
EXICURE, INC. (Filer) CIK: 0001698530 (see all company filings)

EIN.: 815333008 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39011 | Film No.: 25546653
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)